Funder
Takeda
AbbVie, United States
Pfizer, United States
Amgen, United States
Adaptive Biotechnologies
Bristol-Myers Squibb, United States
Pharmacyclics, United States
AstraZeneca, United Kingdom
Genentech
Verastem
Servier, France
ADC Therapeutics
Precision Biosciences
Celgene, Seattle Genetics
Incyte
Cellectis
GlaxoSmithKline
Janssen Scientific Affairs
LLC
Eli Lilly and Co
Cyclacel, Inc
Incyte Corp
Oncoceutics Inc
Bioline Rx
Novartis, Switzerland
Eisai, Japan
Arvinas Inc
Cantargia AB
PTC Therapeutics, United States
Genentech, United States
Hoffman-La Roche, Switzerland
Agios
Immunogen
Pfizer
Ariad
Astex
Cyclacel
Daiichi-Sankyo, Japan
Jazz Pharma
Subject
Cancer Research,Oncology,Hematology
Reference19 articles.
1. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues;Swerdlow,2017
2. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia;Kantarjian;Cancer,2004
3. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993);Marks;Blood,2009
4. Successful subtype oriented treatment strategies in adult T-All: results of 744 patients treated in three consecutive GMALL studies;Hoelzer;Blood,2009
5. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype;Jain;Blood,2016
Cited by
81 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献